Ignite Creation Date:
2025-12-25 @ 4:47 AM
Ignite Modification Date:
2025-12-26 @ 3:49 AM
Study NCT ID:
NCT06655818
Status:
TERMINATED
Last Update Posted:
2025-03-03
First Post:
2024-10-22
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-09
Start Date Type:
ACTUAL
Primary Completion Date:
2024-02-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-02-14
Completion Date Type:
ACTUAL
First Submit Date:
2024-10-22
First Submit QC Date:
None
Study First Post Date:
2024-10-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-02-11
Results First Submit QC Date:
None
Results First Post Date:
2025-03-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-11
Last Update Post Date:
2025-03-03
Last Update Post Date Type:
ACTUAL